Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

• Status: Withdrawn
• Trial end date: 2023-05-01

Summary

This phase II trial studies how well autologous tumor infiltrating lymphocytes (LN-145) and pembrolizumab work in treating patients with transitional cell cancer that cannot be removed by surgery or has spread to other places in the body and have failed cisplatin-based chemotherapy. LN-145 is made up of specialized immune cells called lymphocytes or T cells that are taken from a patient's tumor, grown in a manufacturing facility and infused back into the preconditioned patient to attack the tumor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving LN-145 may help control transitional cell bladder cancer when given together with pembrolizumab

• Phase: Phase 2

Details

• Lead Sponsor: Roswell Park Cancer Institute
• Collaborators: Iovance Biotherapeutics, Inc.; National Cancer Institute (NCI)
• Treatments: Aldesleukin; Cisplatin; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Immunoglobulin G; Immunoglobulins; Interleukin-2; Pembrolizumab; Vidarabine